Abstract:Objective To study the immunological effects of combined immunization of mice with a DNA vaccine and a peptide vaccine consisting of multiple epitopes of latent membrane protein 2(LMP2)from Epstein-Barr virus(EBV).Methods BALB/c female mice were randomly divided into four groups.Group 1mice were immunized with a DNA vaccine delivered by major capsid protein L1of human papillomavirus(HPV)(pcDNA3.1(+)/HPVL1-EBV LMP2multiepitope.i.e.pcHPVL1-EBV LMP2).Group 2mice were immunized with the DNA vaccine and a peptide vaccine consisting of multiple epitopes of EBV LMP2.Group 3was immunized with pcDNA3.1(+)without the target gene(control DNA vaccine)while Group 4was immunized with an irrelevant peptide(control peptide vaccine).The DNA vaccine was injected intramuscularly while the peptide vaccine was injected subcutaneously.The immunization schedule was repeated 4 times at 2-week intervals.Seven weeks after immunization,serum samples from immunized mice were collected to detect EBV-specific IgG,IgA,and HPV L1-specific IgG using ELISA.Nine weeks after immunization,EBV-specific IgG subclass(IgG1and IgG2a)antibodies in serum were detected,and the cytotoxic activity of spleen cells from immunized mice was determined using an LDH release assay. Results Absorbance values(A values)for EBV LMP2-specific IgG and IgA antibodies in serum from mice immunized with the DNA vaccine and peptide vaccine were 1.573±0.025and 0.436±0.033,respectively,while A values for those antibodies in serum from mice immunized with the DNA vaccine alone were1.282±0.051and 0.317±0.022.The difference in A values was statistically significant(F=80.393,27.722,P0.05).However,A values for HPV L1-specific IgG were 0.648±0.063in mice immunized with the DNA vaccine and peptide vaccine but 0.702±0.023in mice immunized with the DNA vaccine alone.This difference in A values was not statistically significant(F=1.952,P0.05).A values for EBV LMP2-specific antibody subclasses IgG1and IgG2a were respectively 0.723±0.023and 0.594±0.084in mice immunized with the DNA vaccine alone,so these values did not differ significantly(F=6.643,P0.05)from those in the controls.In contrast,A values for EBV LMP2-specific antibody subclasses IgG1and IgG2awere respectively 0.897±0.042and 0.629±0.035in mice immunized with the DNA vaccine and peptide vaccine,so these values did differ significantly(F=72.306,P0.05)from those in the controls.At an effector-to-target cell(E:T)ratio of 10,the cytotoxicity(%)of splenocytes from mice immunized with the DNA and peptide vaccine was 27.70% while the cytotoxicity of splenocytes from mice immunized with the DNA vaccine alone was21.50%.The difference in cytotoxicity of splenocytes was statistically significant(F=51.559,P0.05). Conclusion Combined immunization with a DNA vaccine and peptide vaccine enhanced the cytotoxicity of splenocytes and it also induced a significant humoral immune response.This immunization strategy may provide a guide to immunotherapy for EBV-associated tumors.

Immunogenicity of A Multiepitope Plasmid Dna Encoding T and B Lymphocyte Epitopes from Latent Membrane Protein 2 (lmp2) of Epstein-Barr Virus As A Vaccine in Mice

Prokaryotic Expression and Antigen Characteristics of EB Virus Latent Membrane Protein 2 ( EBV-LMP2) Multi-Epitopes

Study on Combined Immunization with a DNA Vaccine and a Peptide Vaccine Consisting of Multiple Epitopes of Latent Membrane Protein 2 from Epstein-Barr Virus

Expression of HPV6b L1/EBV LMP2 Multiepitope and Immunogenicity in Mice.

Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice

Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.

Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice

A Novel Vaccine Candidate Based on Chimeric Virus-Like Particle Displaying Multiple Conserved Epitope Peptides Induced Neutralizing Antibodies Against EBV Infection

Immunization with Epstein–Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge

Induction of the Epstein-Barr Virus Latent Membrane Protein 2 Antigen-specific Cytotoxic T Lymphocytes Using Human Leukocyte Antigen Tetramer-based Artificial Antigen-presenting Cells

TianTan vaccinia virus-based EBV vaccines targeting both latent and lytic antigens elicits potent immunity against lethal EBV challenge in humanized mice

EBV LMP2A-specific T Cell Immune Responses Elicited by Dendritic Cells Loaded with LMP2A Protein

mRNA‐based Vaccines Targeting the T‐cell Epitope‐rich Domain of Epstein Barr Virus Latent Proteins Elicit Robust Anti‐Tumor Immunity in Mice

In vitro anti-tumor immune response induced by dendritic cells transfected with EBV-LMP2 recombinant adenovirus

Evaluation of Epstein-Barr Virus Latent Membrane Protein 2 Specific T-Cell Receptors Driven by T-Cell Specific Promoters Using Lentiviral Vector

[Sequence analysis of the CTL epitopes in transmembrane region of latent membrane protein 2 of Epstein-Barr virus derived from nasopharyngeal carcinoma cells].

An Insect Cell-Derived Extracellular Vesicle-Based Gb Vaccine Elicits Robust Adaptive Immune Responses Against Epstein-Barr Virus

Immunoinformatic and systems biology approaches to predict and validate peptide vaccines against Epstein–Barr virus (EBV)

[Construction and Identification of Recombinant Retroviral Vector and Stable Cell Line Expressing Latent Membrane Protein 2A of Epstein-Barr Virus].

Constructing TC-1-GLUC-LMP2 Model Tumor Cells to Evaluate the Anti-Tumor Effects of LMP2-Related Vaccines.

Induction of EBV Latent Membrane Protein-2A (Lmp2a)-Specific T Cells and Construction of Individualized TCR-engineered T Cells for EBV-associated Malignancies